

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/902,176
				Filing Date	July 10, 2001
				First Named Inventor	Schreiber
				Art Unit	1645
				Examiner Name	Not yet assigned
				Attorney Docket Number	25481-P001US
Sheet	1	of	2		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code 3 - Number 4 - Kind Code 5 (if known)				
48		WO 00/31293	06-02-2000	Morris	Whole document	

Examiner Signature	<i>Callan Cahn</i>	Date Considered	10/24/03
-----------------------	--------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231**



PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/902,176
		Filing Date	July 10, 2001
		First Named Inventor	Schreiber
		Group Art Unit	1645
		Examiner Name	Not yet assigned
		Attorney Docket Number	25481-P001US
Sheet	2	of	2

RECEIVED
JAN 2 9 2002
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JS	-	SMITH et al.; Human Tumor Necrosis Factor Receptor mRNA; Database EMHUM6 'Online!'; ID HSNFR, June 1990	
JS	-	SYNERGEN, Inc.; 40kD TNF Inhibitor Precursor; Database GCG_GENESEQ_P 'Online!'; R11001 January 1991	
JS	-	SMITH; Fibroblast Derived TNF-R; Database GCG_GENESEQ_P 'Online!'; ID: R42058, April 1994	
JS	-	BELTINGER, et al.; Physical Mapping and Genomic Structure of the Human TNFR2 Gene; Genomics 35, 94-11 (1996); Article No. 0327; 1996	
JS	-	RAU, et al.; Polymorphisms of Tumor Necrosis Factor Receptor 2 are Not Associated with Insulin-Dependent diabetes Mellitus or Graves' Disease; Tissue Antigens; Vol 49, No. 5, 1997, pages 535-536	
JS	-	VAN DEVENTER; Immunomodulation of Chron's Disease Using TNF-alpha Neutralizing Monoclonal Antibodies; Clinical Nutrition, GB, Churchill, Livingston, London; 1997	
JS	-	CHO, et al; Identification of Novel Susceptibility Loci for Inflammatory Bowel disease on Chromosomes 1p, 3q, and 4q: Evidence for Epistasis Between 1p and IBD1; Proceedings of the National Academy of Sciences of the United States; vol 95, no. 13; June 23, 1998; pages 7502-7507	
JS	-	KOMATA, et al; Association of Tumor Necrosis Factor Receptor 2 (TNFR2) Polymorphism with Susceptibility to systemic Lupus Erythematosus; Tissue Antigens, Vol 53, No. 6; June 1999; pages 527-533	
JS	-	PANTELEDIS, et al.; Polymorphic Analysis of the High-Affinity Tumor Necrosis Factor Receptor 2; Tissue Antigens, Vol 54, Dec. 1999; pages 585-591	
JS	-	AL-ANSARI, et al.; Tumor Necrosis Factor Receptor II (TNFR2) Exon 6 Polymorphism in systemic Lupus Erythematosus; Tissue Antigens, Vol 55, No. 1; January 2000, pages 97-99	
JS	-	LOUIS, et al.; Tumour Necrosis Factor (TNF) Gene Polymorphism in Crohn's Disease (CD): Influence on Disease Behaviour?; Clinical and Experimental Immunology, Vol 119, No. 1, January 2000; pages 64-68	

Examiner Signature	<i>Sally Jan</i>	Date Considered	10/24/03
--------------------	------------------	-----------------	----------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.